Net Loss Per Share

3 Months Ended

Mar. 31, 2022

Earnings Per Share [Abstract]

Net Loss Per Share

Note 17 — Net Loss Per Share

The respective “Net loss per share - attributable to PAVmed Inc. - basic and diluted” and “Net loss per share - attributable to PAVmed Inc. common stockholders - basic and diluted” - for the periods indicated - is as follows:

	Three Months Ended March 31,
	2022			2021
Numerator
Net loss - before noncontrolling interest	$	(19,633	)	$	(10,110	)
Net loss attributable to noncontrolling interest		2,761			679
Net loss - as reported, attributable to PAVmed Inc.	$	(16,872	)	$	(9,431	)
Series B Convertible Preferred Stock dividends – earned	$	(68	)	$	(75	)
Net loss attributable to PAVmed Inc. common stockholders	$	(16,940	)	$	(9,506	)
Denominator
Weighted average common shares outstanding, basic and diluted		86,336,427			73,954,126
Loss per share
Basic and diluted
Net loss - as reported, attributable to PAVmed Inc.	$	(0.20	)	$	(0.13	)
Net loss attributable to PAVmed Inc. common stockholders	$	(0.20	)	$	(0.13	)

The common stock equivalents have been excluded from the computation of diluted weighted average shares outstanding as their inclusion would be anti-dilutive, are as follows:

The Series B Convertible Preferred Stock dividends earned as of the each of the respective periods noted, are included in the calculation of basic and diluted net loss attributable to PAVmed Inc. common stockholders for each respective period presented. Notwithstanding, the Series B Convertible Preferred Stock dividends are recognized as a dividend payable only upon the dividend being declared payable by the Company’s board of directors.

Basic weighted-average number of shares of common stock outstanding for the periods ended March 31, 2022 and 2021 include the shares of the Company issued and outstanding during such periods, each on a weighted average basis. The basic weighted average number of shares common stock outstanding excludes common stock equivalent incremental shares, while diluted weighted average number of shares outstanding includes such incremental shares. However, as the Company was in a loss position for all periods presented, basic and diluted weighted average shares outstanding are the same, as the inclusion of the incremental shares would be anti-dilutive. The common stock equivalents excluded from the computation of diluted weighted average shares outstanding are as follows:

	March 31,
	2022		2021
Stock options and restricted stock awards		12,368,292		8,539,362
Series Z Warrants		11,937,450		15,954,722
Series W Warrants		—		381,818
Series B Convertible Preferred Stock		1,136,210		1,241,438
Total		25,441,952		26,117,340

The total stock options and restricted stock awards are inclusive of 500,854 stock options as of March 31, 2022 and 2021; and 100,000 restricted stock awards as of March 31, 2022, granted outside the PAVmed Inc. 2014 Equity Plan.